Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 23. (Cancelled)

24. (Currently Amended) A method for treating a neurodegenerative disorder or disease in which there is accumulation of misfolded and/or aggregated proteins, excluding prion-related diseases selected from the group consisting of Huntington's disease and Alzheimer's disease, said method comprising administering to an individual in need thereof an active agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

25. (Cancelled)

26. (Currently Amended) A—The method in accordance with claim 2524, wherein said active agent is Copolymer 1.

27. (Cancelled)

- 28. (Withdrawn Currently Amended) A The method in accordance with claim 2524, wherein said active agent is T cells which have been activated by Copolymer 1.
- disease progression, and/or for protection from
 neurodegeneration and/or protection from glutamate toxicity in
 a patient suffering from a neurodegenerative disease or
 disorder selected from the group consisting of Huntington's
 disease, and Alzheimer's disease and Parkinson's disease,
 which comprises immunizing administering to said patient in
 need with a therapeutically effective amount of an active
 agent selected from the group consisting of (i) Copolymer 1,
 (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1related polypeptide, and (iv) T cells activated with (i), (ii)
 or (iii).

30. (Cancelled)

31. (Withdrawn - Currently Amended) A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from Alzheimer's disease, which comprises administering to an individual in need thereof an effective

amount of an <u>active</u> agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

32. (Currently Amended) A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection protection from glutamate toxicity in a patient suffering from Huntington's disease, which comprises administering to an individual said patient in need thereof an effective amount of an active agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

33. (Cancelled)

34. (Currently Amended) A method for treatment of a patient suffering from a neurodegenerative disease or disorder selected from the group consisting of Huntington's disease, and Alzheimer's disease and Parkinson's disease, which comprises immunizing said patient with a vaccine comprising an amount of Copolymer 1 effective for reducing disease progression in said patient.

- 35. (Currently Amended) A method for treatment of a patient suffering from neurodegenerative disease or disorder selected from the group consisting of Huntington's disease, and Alzheimer's disease and Parkinson's disease, which comprises immunizing said patient with a vaccine comprising an amount of Copolymer 1 effective for protection from neurodegeneration in said patient.
- 36. (Currently Amended) A method for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with Huntington's disease, or Alzheimer's disease or Parkinson's disease, said method comprising administering to an individual in need an active agent selected from the group consisting consisting of (i) Copolymer, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with(i), (ii) or (iii).
- 37. (Currently Amended) A—The method according to claim 36, wherein said active agent is Copolymer 1.

5